newsfilter
← Latest News
GlobeNewswire·

Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

ALPS
  • Alps Group Inc announced a potential expansion of its exosome pipeline beyond the CELESOME(+) program following a published preliminary retrospective clinical case series.
  • The study, registered with the National Medical Research Register in Malaysia, investigated nebulized human umbilical cord mesenchymal stem cell (hUCMSC) derived exosomes for asthma & COPD patients.
  • Findings from the publication in SAGE Open Medical Case Reports indicated improvements in pulmonary function, stable inflammatory markers, & no significant adverse effects.
  • The treatment protocol involved weekly 30-minute nebulization of a 1 ml exosome solution mixed with 5 ml saline for five weeks.
  • CEO Dr. Tham Seng Kong emphasized that while results are promising, larger-scale controlled studies are required to confirm efficacy & establish standardized protocols.
  • Current global disease burdens include approximately 260 million asthma patients & 400 million COPD patients, with existing therapies largely focusing on symptom management.
  • The release includes forward-looking statements & disclaimers stating there is no guarantee of successful clinical development or regulatory approval.
  • Study details are accessible via the peer-reviewed article at the provided SAGE Open Medical Case Reports URL.